New York location for dermatology study by Equity Medical
Study Location
New York
Office Address

200 Amsterdam Ave. New York, NY 10023

Office Phone
646-413-6020

Overview

Recruiting start date
  • Currently Enrolling
Duration
  • 24 Weeks
Population

Individuals aged 12 and above with moderate-to-severe Atopic Dermatitis (AD) that is inadequately controlled with topical treatments.

Study Drug

Subcutaneous Amlitelimab injection (80%) or placebo (20%) monotherapy injection. Subjects randomized to placebo who are non-responders will receive drug after 20 weeks.

Background: Amlitelimab, an OX40 ligand inhibitor, showed best-in-class efficacy, potential disease modification, and no dose-responsive safety signals in its phase 2B trial. This study aims to further explore the efficacy and safety of Amlitelimab in a larger population.

Inclusion Criteria
  • EASI score greater than 16
  • IGA score of 3 or 4
  • Body surface area (BSA) affected greater than 10%
  • Weekly average pruritus-numerical rating scale (PP-NRS) score greater than 4
Exclusion Criteria
  • History of significant immunosuppression
  • Malignancy
  • Solid organ or stem cell transplant
  • Active infection
Prior/Concomitant Therapy

Previous use of oral or topical JAK inhibitors is allowed if not exceeding 6 months. A 12-week washout period is required for biologics such as Dupilumab, Tralokinumab, and Lebrikizumab prior to the baseline visit.

Compensation
  • Participants will receive $50 per visit
Studies
Contact us to join a dermatology study clinical trial

Contact Us Today!

Whether it be eczema, dandruff, or psoriasis, being a part of our research is an impactful way to explore treatments and medications. Even if there isn’t a current study that’s a perfect fit for you, take the first step and sign up to learn more and be considered for future studies in New York and Kentucky. Click the button below to get started!